BACKGROUND: Chronic alcohol exposure can alter glucocorticoid receptor (GR) function in some brain areas that promotes escalated and compulsive-like alcohol intake. GR antagonism can prevent dependence-induced escalation in drinking, but very little is known about the role of GR in regulating high-risk nondependent alcohol intake. Here, we investigate the role of GR in regulating binge-like drinking and aversive responses to alcohol in the High Drinking in the Dark (HDID-1) mice, which have been selectively bred for high blood ethanol (EtOH) concentrations (BECs) in the Drinking in the Dark (DID) test, and in their founder line, the HS/NPT. METHODS: In separate experiments, male and female HDID-1 mice were administered one of several compounds that inhibited GR or its negative regulator, FKBP51 (mifepristone [12.5, 25, 50, 100 mg/kg], CORT113176 [20, 40, 80 mg/kg], and SAFit2 [10, 20, 40 mg/kg]) during a 2-day DID task. EtOH consumption and BECs were measured. EtOH conditioned taste and place aversion (CTA and CPA, respectively) were measured in separate HDID-1 mice after mifepristone administration to assess GR's role in regulating the conditioned aversive effects of EtOH. Lastly, HS/NPT mice were administered CORT113176 during DID to assess whether dissimilar effects from those of HDID-1 would be observed, which could suggest that selective breeding had altered sensitivity to the effects of GR antagonism on binge-like drinking. RESULTS: GR antagonism (with both mifepristone and CORT113176) selectively reduced binge-like EtOH intake and BECs in the HDID-1 mice, while inhibition of FKBP51 did not alter intake or BECs. In contrast, GR antagonism had no effect on EtOH intake or BECs in the HS/NPT mice. Although HDID-1 mice exhibit attenuated EtOH CTA, mifepristone administration did not enhance the aversive effects of EtOH in either a CTA or CPA task. CONCLUSION: These data suggest that the selection process increased sensitivity to GR antagonism on EtOH intake in the HDID-1 mice, and support a role for the GR as a genetic risk factor for high-risk alcohol intake.
BACKGROUND: Chronic alcohol exposure can alter glucocorticoid receptor (GR) function in some brain areas that promotes escalated and compulsive-like alcohol intake. GR antagonism can prevent dependence-induced escalation in drinking, but very little is known about the role of GR in regulating high-risk nondependent alcohol intake. Here, we investigate the role of GR in regulating binge-like drinking and aversive responses to alcohol in the High Drinking in the Dark (HDID-1) mice, which have been selectively bred for high blood ethanol (EtOH) concentrations (BECs) in the Drinking in the Dark (DID) test, and in their founder line, the HS/NPT. METHODS: In separate experiments, male and female HDID-1mice were administered one of several compounds that inhibited GR or its negative regulator, FKBP51 (mifepristone [12.5, 25, 50, 100 mg/kg], CORT113176 [20, 40, 80 mg/kg], and SAFit2 [10, 20, 40 mg/kg]) during a 2-day DID task. EtOH consumption and BECs were measured. EtOH conditioned taste and place aversion (CTA and CPA, respectively) were measured in separate HDID-1mice after mifepristone administration to assess GR's role in regulating the conditioned aversive effects of EtOH. Lastly, HS/NPT mice were administered CORT113176 during DID to assess whether dissimilar effects from those of HDID-1 would be observed, which could suggest that selective breeding had altered sensitivity to the effects of GR antagonism on binge-like drinking. RESULTS:GR antagonism (with both mifepristone and CORT113176) selectively reduced binge-like EtOH intake and BECs in the HDID-1mice, while inhibition of FKBP51 did not alter intake or BECs. In contrast, GR antagonism had no effect on EtOH intake or BECs in the HS/NPT mice. Although HDID-1mice exhibit attenuated EtOH CTA, mifepristone administration did not enhance the aversive effects of EtOH in either a CTA or CPA task. CONCLUSION: These data suggest that the selection process increased sensitivity to GR antagonism on EtOH intake in the HDID-1mice, and support a role for the GR as a genetic risk factor for high-risk alcohol intake.
Authors: Joshua L Gowin; Matthew E Sloan; Bethany L Stangl; Vatsalya Vatsalya; Vijay A Ramchandani Journal: Am J Psychiatry Date: 2017-08-04 Impact factor: 18.112
Authors: Gabriela M Wochnik; Joëlle Rüegg; G Alexander Abel; Ulrike Schmidt; Florian Holsboer; Theo Rein Journal: J Biol Chem Date: 2004-12-09 Impact factor: 5.157
Authors: Elisabeth B Binder; Daria Salyakina; Peter Lichtner; Gabriele M Wochnik; Marcus Ising; Benno Pütz; Sergi Papiol; Shaun Seaman; Susanne Lucae; Martin A Kohli; Thomas Nickel; Heike E Künzel; Brigitte Fuchs; Matthias Majer; Andrea Pfennig; Nikola Kern; Jürgen Brunner; Sieglinde Modell; Thomas Baghai; Tobias Deiml; Peter Zill; Brigitta Bondy; Rainer Rupprecht; Thomas Messer; Oliver Köhnlein; Heike Dabitz; Tanja Brückl; Nina Müller; Hildegard Pfister; Roselind Lieb; Jakob C Mueller; Elin Lõhmussaar; Tim M Strom; Thomas Bettecken; Thomas Meitinger; Manfred Uhr; Theo Rein; Florian Holsboer; Bertram Muller-Myhsok Journal: Nat Genet Date: 2004-11-21 Impact factor: 38.330
Authors: Jakob Hartmann; Klaus V Wagner; Steffen Gaali; Alexander Kirschner; Christian Kozany; Gerd Rühter; Nina Dedic; Alexander S Häusl; Lianne Hoeijmakers; Sören Westerholz; Christian Namendorf; Tamara Gerlach; Manfred Uhr; Alon Chen; Jan M Deussing; Florian Holsboer; Felix Hausch; Mathias V Schmidt Journal: J Neurosci Date: 2015-06-17 Impact factor: 6.167
Authors: John C Crabbe; Jason P Schlumbohm; Wyatt Hack; Amanda M Barkley-Levenson; Pamela Metten; K Matthew Lattal Journal: Alcohol Date: 2016-02-17 Impact factor: 2.405
Authors: Andrea Rotter; Theresa Biermann; Davide Amato; Gunter Schumann; Sylvane Desrivieres; Johannes Kornhuber; Christian P Müller Journal: Brain Res Bull Date: 2012-05-17 Impact factor: 4.077
Authors: Mehrdad Alavi; Andrey E Ryabinin; Melinda L Helms; Michelle A Nipper; Leslie L Devaud; Deborah A Finn Journal: Front Behav Neurosci Date: 2022-05-11 Impact factor: 3.617
Authors: Thaddeus M Barney; Andrew S Vore; Sarah L Trapp; Cristal L Finkenberg; Dominique R Pugliesi; Megha M Schmalzle; Shani H Evans; Elena I Varlinskaya; Terrence Deak Journal: Neuropharmacology Date: 2022-03-24 Impact factor: 5.273
Authors: Vanessa A Jimenez; Nicole A R Walter; Tatiana A Shnitko; Natali Newman; Kaya Diem; Lauren Vanderhooft; Hazel Hunt; Kathleen A Grant Journal: J Pharmacol Exp Ther Date: 2020-09-01 Impact factor: 4.030
Authors: M Adrienne McGinn; Brendan J Tunstall; Joel E Schlosburg; Adriana Gregory-Flores; Olivier George; Giordano de Guglielmo; Barbara J Mason; Hazel J Hunt; George F Koob; Leandro F Vendruscolo Journal: Neuropharmacology Date: 2021-02-26 Impact factor: 5.250
Authors: Antonia M Savarese; Angela R Ozburn; Amanda M Barkley-Levenson; Pamela Metten; John C Crabbe Journal: Alcohol Date: 2021-02-06 Impact factor: 2.558
Authors: Kolter B Grigsby; Antonia M Savarese; Pamela Metten; Barbara J Mason; Yuri A Blednov; John C Crabbe; Angela R Ozburn Journal: Neurosci Insights Date: 2020-11-25